NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis $300.43 -10.47 (-3.37%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$312.21 +11.79 (+3.92%) As of 11/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Praxis Precision Medicines Stock (NASDAQ:PRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PRAX alerts:Sign Up Key Stats Today's Range$298.54▼$314.1550-Day Range$239.02▼$346.2152-Week Range$160.11▼$392.70Volume806,145 shsAverage Volume480,688 shsMarket Capitalization$8.40 billionP/E RatioN/ADividend YieldN/APrice Target$660.50Consensus RatingModerate Buy Company Overview Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments. Praxis is headquartered in Boston, Massachusetts, and is led by co-founder and Chief Executive Officer Marcio Souza.AI Generated. May Contain Errors. Read More Praxis Precision Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScorePRAX MarketRank™: 3.151856487275 of 5 starsPraxis Precision Medicines scored higher than 63% of companies evaluated by MarketBeat, and ranked 386th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 18 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialPraxis Precision Medicines has a consensus price target of $660.50, representing about 119.9% upside from its current price of $300.43.Amount of Analyst CoveragePraxis Precision Medicines has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Praxis Precision Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($13.72) to ($12.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -23.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -23.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.54% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 8.69.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 7.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.53 News SentimentPraxis Precision Medicines has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Praxis Precision Medicines this week, compared to 6 articles on an average week.Search Interest9 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows3 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by Insiders3.00% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRAX Stock News HeadlinesLaunch Plans Could Be A Game Changer For Praxis Precision Medicines Stock (PRAX)2 hours ago | finance.yahoo.comPraxis Precision: Steady Hands For A Shaky PDUFA Season (Initiating With A Speculative Buy)November 19 at 2:17 PM | seekingalpha.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet. | Paradigm Press (Ad)Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $1,050.00November 19 at 3:24 AM | americanbankingnews.com3 ‘Strong Buy’ High-Risk Stocks That Could Deliver 100% or More GainsNovember 18 at 5:28 PM | tipranks.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Expected to Rise, Robert W. Baird Analyst SaysNovember 18 at 2:00 AM | americanbankingnews.comTranscript : Praxis Precision Medicines, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 10:40 AMNovember 16, 2026 | marketscreener.comMPraxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 16, 2026 | seekingalpha.comSee More Headlines PRAX Stock Analysis - Frequently Asked Questions How have PRAX shares performed this year? Praxis Precision Medicines' stock was trading at $294.74 at the beginning of the year. Since then, PRAX shares have increased by 1.9% and is now trading at $300.43. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced its quarterly earnings results on Monday, November, 9th. The company reported ($3.23) EPS for the quarter, topping the consensus estimate of ($3.54) by $0.31. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines's stock reverse split before market open on Wednesday, November 29th 2023.The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $170 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Top institutional investors of Praxis Precision Medicines include State Street Corp (3.74%), Goldman Sachs Group Inc. (1.76%), Logos Global Management LP (1.52%) and Pictet Asset Management Holding SA (1.01%). Insiders that own company stock include Alex Nemiroff, Lauren Mastrocola and Jill Desimone. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Praxis Precision Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include Micron Technology (MU), NVIDIA (NVDA), Symbotic (SYM), Taiwan Semiconductor Manufacturing (TSM), Bloom Energy (BE), Palantir Technologies (PLTR) and Applied Materials (AMAT). Company Calendar Last Earnings11/09/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PRAX's financial health is in the Green zone, according to TradeSmith. PRAX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRAX CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees168Year Founded2015Price Target and Rating Average Price Target for Praxis Precision Medicines$660.50 High Price Target$1,201.00 Low Price Target$189.00 Potential Upside/Downside+119.9%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($12.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$303.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.41% Return on Assets-28.19% Debt Debt-to-Equity RatioN/A Current Ratio14.53 Quick Ratio14.53 Sales & Book Value Annual Sales$8.55 million Price / Sales982.11 Cash FlowN/A Price / Cash FlowN/A Book Value$45.06 per share Price / Book6.67Miscellaneous Outstanding Shares27,950,000Free Float27,113,000Market Cap$8.40 billion OptionableOptionable Beta2.85 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PRAX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.